Simulations Plus

Simulations Plus is a leading company in the field of drug discovery and development, providing innovative solutions to improve health.

Headquarters

Year Founded

Search Tags

Pharmacokinetics modeling, ADMET prediction, Drug development software

About Us

Simulations Plus develops software and leverages AI and machine learning for drug discovery and development, focusing on modeling and simulation tools. Their products include GastroPlus for pharmacokinetics, ADMET Predictor for molecular property prediction, and DDDPlus for dissolution analysis. The company offers solutions for physiologically-based pharmacokinetics, quantitative systems pharmacology, and population PK/PD modeling. They also provide consulting services to support pharmaceutical research, clinical trials, and regulatory submissions, helping clients improve drug development efficiency and success rates.

Trending Companies

Latest Articles

Engineer intelligent, AI-driven supply chain operations. Discover what next-generation leaders must master to design resilient, data-driven, high-performing global networks.

The Future of Supply Chain Leadership: Why the Next Generation Will Engineer Intelligence, Not Just Manage It

Supply chain leadership is being redefined by AI, intelligent automation, and agentic decision-making, demanding leaders who can engineer end-to-end intelligence rather than simply manage workflows. This article explores how next-generation supply chain leaders will combine data, algorithms, and human judgment to build resilient, adaptive, and high-performing global operations.

Read More >
Medicare will pilot AI-driven prior authorization in 2026 across six states, targeting high-risk services while clinicians make final decisions.

AI-Powered Prior Authorization Comes to Traditional Medicare

Traditional Medicare will pilot AI-assisted prior authorization in 2026 across six states, focusing on high-risk outpatient services. Clinicians retain final say, but incentives and access concerns loom as CMS tests fraud reduction and “gold card” exemptions. Here’s what providers and patients should know.

Read More >